{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-087465","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2025-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.620914+00:00","generated_at":"2026-05-17T08:24:54.294116+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Theriva Biologics shareholders approve equity plan increase and elect directors at annual meeting","bullets":["Shareholders approved Amendment No. 3 to increase shares under 2020 Stock Incentive Plan from 2.5M to 4.5M.","All four director nominees elected: Jeffrey J. Kraws, Steven A. Shallcross, John Monahan, Jeffrey Wolf.","Ratified BDO USA, P.C. as independent auditor for FY2025 with 3.61M votes for.","Advisory vote on executive compensation approved; future frequency set at three years.","Vote totals for each proposal are disclosed; broker non-votes totaled 2,212,112 shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-087465","json":"https://secwatch.observer/filing/0001104659-25-087465.json","markdown":"https://secwatch.observer/filing/0001104659-25-087465.md","text":"https://secwatch.observer/filing/0001104659-25-087465.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465925087465/0001104659-25-087465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465925087465/tm2525057d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:24:54.294116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}